Pancreatic Cancer Research

ResearcherUniversitätsmedizin GöttingenNo recent work listed

Jens Stieler

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5038246369. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 3 papers · 2014: 7 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 18

  1. Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. First author DOI 10.3390/jcm11164905↗
  2. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Co-author DOI 10.1200/jco.2017.72.6463↗
  3. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. Last author DOI 10.1097/mpa.0000000000000533↗
  4. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… Co-author DOI 10.1016/j.ejca.2015.05.005↗
  5. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. Co-author DOI 10.1200/jco.2014.55.1481↗
  6. [Multimodal treatment of pancreatic cancer]. Co-author DOI 10.1007/s00108-013-3316-6↗
  7. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Co-author DOI 10.1038/bjc.2014.495↗
  8. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Co-author DOI 10.1093/annonc/mdu084↗
  9. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000077↗
  10. Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy. Co-author DOI 10.1155/2014/452089↗
  11. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. Co-author DOI 10.1186/1471-2407-14-204↗
  12. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from … Co-author DOI 10.1200/jco.2013.53.6995↗
  13. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. Co-author DOI 10.1002/jso.23409↗
  14. [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Co-author DOI 10.1055/s-0033-1349608↗
  15. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Co-author DOI 10.3389/fonc.2013.00155↗
  16. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Co-author DOI 10.1186/1475-2891-11-52↗
  17. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CO… Co-author DOI 10.1007/s00280-011-1602-3↗
  18. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase I… Co-author DOI 10.1016/j.ejca.2011.04.011↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanno B. Riess · 17 shared papers, 2011–2022 · strength 0.81
  2. Uwe Pelzer · 16 shared papers, 2011–2022 · strength 0.78
  3. Marianne Sinn · 15 shared papers, 2013–2022 · strength 0.76
  4. Jana Käthe Striefler · 9 shared papers, 2013–2022 · strength 0.48
  5. Helmut Oettle · 10 shared papers, 2011–2022 · strength 0.48
  6. Marcus Bahra · 9 shared papers, 2013–2017 · strength 0.37
  7. Bruno Valentin Sinn · 5 shared papers, 2013–2015 · strength 0.19
  8. Carsten Denkert · 5 shared papers, 2013–2015 · strength 0.19
  9. Pirus Ghadjar · 1 shared paper, 2022 · strength 0.14
  10. Thomas Malinka · 1 shared paper, 2022 · strength 0.14
  11. Christopher Neumann · 1 shared paper, 2022 · strength 0.14
  12. Philipp Lohneis · 3 shared papers, 2014–2015 · strength 0.12
  13. Andreas Hilbig · 2 shared papers, 2013–2014 · strength 0.09
  14. Michael B. Ghadimi · 1 shared paper, 2017 · strength 0.05
  15. Bettina Rau · 1 shared paper, 2017 · strength 0.05
  16. Robert Grützmann · 1 shared paper, 2017 · strength 0.05
  17. Dirk Waldschmidt · 1 shared paper, 2017 · strength 0.05
  18. Bernhard Gebauer · 1 shared paper, 2014 · strength 0.04
  19. Timm Denecke · 1 shared paper, 2015 · strength 0.04
  20. Tim F. Greten · 1 shared paper, 2014 · strength 0.04
  21. Wilko Weichert · 1 shared paper, 2014 · strength 0.04
  22. Carsten Kamphues · 1 shared paper, 2014 · strength 0.04
  23. Frederick Klauschen · 1 shared paper, 2014 · strength 0.04
  24. Albrecht Stenzinger · 1 shared paper, 2014 · strength 0.04
  25. Claudia J. Nitsche · 1 shared paper, 2012 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.